Genetic variations in abcb1 and cyp3a5 as well as sex influence quinine disposition among ugandans

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 346-352

  Mukonzo, Jackson K ^a,b   Waako, Paul ^b   Ogwal Okeng, Jasper ^b   Gustafsson, Lars L ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

ABCB1; CYP3A5; Genetic polymorphism; Quinine; Ugandans

Indexed keywords

3 HYDROXYQUININE; ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; CYTOCHROME P450 3A5; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 1; QUININE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UGANDA; VOLUNTEER;

AFRICAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CYTOCHROME P-450 CYP3A; FEMALE; GENES; GENETIC VARIATION; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINIDINE; QUININE; SEX FACTORS; UGANDA;

EID: 77952950824     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181da79d6     Document Type: Article

References (40)

1. Pongtavornpinyo W, Yeung S, Hastings IM, et al. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. Malar J. 2008;7:229.
2. Teka H, Petros B, Yamuah L, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.
3. Newton PN, Angus BJ, Chierakul W, et al. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37:7-16.
4. Goldenberg AM, Wexler LF. Quinine overdose: review of toxicity and treatment. Clin Cardiol. 1988;11:716-718.
5. Karlsson KK, Hellgren U, Alvan G, et al. Audiometry as a possible indicator of quinine plasma concentration during treatment of malaria. Trans R Soc Trop Med Hyg. 1990;84:765-767.
6. AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007;53: 385-391.
7. Mirghani RA, Ericsson O, Cook J, et al. Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;754: 57-64.
8. Mirghani RA, Ericsson O, Tybring G, et al. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol. 2003;59:23-28.
9. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16:637-645.
10. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
11. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16:637-645.
12. Hayeshi R, Masimirembwa C, Mukanganyama S, et al. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29:70-81.
13. Pussard E, Merzouk M, Barennes H. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur J Pharm Sci. 2007;32:123-127.
14. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-174.
15. Sanchez CP, Rotmann A, Stein WD, et al. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol Microbiol. 2008;70:786-798.
16. Dua VK, Sarin R, Prakash A. Determination of quinine in serum, plasma, red blood cells and whole blood in healthy and Plasmodium falciparum malaria cases by high-performance liquid chromatography. J Chromatogr. 1993;614:87-93.
17. Vieira JL, Midio AF. Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil. Ther Drug Monit. 2001;23:612-615.
18. Achan J, Byarugaba J, Barennes H, et al. Rectal versus intravenous quinine for the treatment of childhood cerebral malaria in Kampala, Uganda: a randomized, double-blind clinical trial. Clin Infect Dis. 2007; 45:1446-1452.
19. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemo-ther. 2008;52:1589-1596.
20. Lindroos K, Liljedahl U, Syvanen AC. Genotyping SNPs by mini-sequencing primer extension using oligonucleotide microarrays. Methods Mol Biol. 2003;212:149-165.
21. Lovmar L, Syvanen AC. Genotyping single-nucleotide polymorphisms by minisequencing using tag arrays. Methods Mol Med. 2005;114:79-92.
22. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12:437-450.
23. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38:978-988.
24. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33-60.
25. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329-342.
26. Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol. 2008;48:1350-1355.
27. Diczfalusy U, Miura J, Roh HK, et al. 4beta-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharma-cogenet Genomics. 2008;18:201-208.
28. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4: 413-424.
29. del Carmen Carrasco-Portugal M, Lujan M, Flores-Murrieta FJ. Evaluation of gender in the oral pharmacokinetics of clindamycin in humans. Biopharm Drug Dispos. 2008;29:427-430.
30. Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009; 68:690-699.
31. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143-157.
32. Harris RZ, Tsunoda SM, Mroczkowski P, et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther. 1996;59:429-435.
33. Gorski JC, Vannaprasaht S, Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275-287.
34. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-121.
35. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275:1011-1018.
36. Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol. 1992;44:806-811.
37. Kishino S, Nomura A, Itoh S, et al. Age-and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol. 2002;58:621-628.
38. Atumwikirize W. Drug Information and Monitoring Service in Uganda; Studies on Drug Information Sources and Adverse Drug Reactions. PhD thesis, Makerere University, Uganda (Kampala, 2009).
39. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bio-availability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69-74.
40. Allabi AC, Horsmans Y, Issaoui B, et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol. 2005;61:97-102.